Geode Capital Management LLC Has $254.19 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Geode Capital Management LLC increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,276,502 shares of the medical research company’s stock after purchasing an additional 9,756 shares during the quarter. Geode Capital Management LLC’s holdings in Charles River Laboratories International were worth $254,186,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. increased its position in shares of Charles River Laboratories International by 84.5% during the 3rd quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after purchasing an additional 47,954 shares in the last quarter. Madison Asset Management LLC acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $1,935,000. JPMorgan Chase & Co. increased its position in shares of Charles River Laboratories International by 14.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after purchasing an additional 40,073 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $533,000. Finally, Van Berkom & Associates Inc. increased its position in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. Van Berkom & Associates Inc. now owns 496,911 shares of the medical research company’s stock worth $77,747,000 after purchasing an additional 9,962 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 4.1%

CRL opened at $174.56 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $8.41 billion, a PE ratio of -46.43, a PEG ratio of 2.08 and a beta of 1.46. Charles River Laboratories International, Inc. has a 1-year low of $132.65 and a 1-year high of $228.88. The firm has a 50-day moving average price of $169.66 and a two-hundred day moving average price of $181.34.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CRL shares. TD Cowen dropped their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. UBS Group raised their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Barclays raised their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Finally, Evercore restated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $208.50.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.